Cargando…

The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first‐line therapy for patients with metastatic castration‐resistant prostate cancer

BACKGROUND: To explore whether metastatic castration‐resistant prostate cancer (mCRPC) patients with distinct intraductal carcinoma of the prostate (IDC‐P) subtypes respond differently to abiraterone and docetaxel treatment. METHODS: We retrospectively analyzed data of 170 mCRPC patients receiving a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Zhipeng, Zhu, Sha, Zhao, Jinge, Nie, Ling, Chen, Xueqin, Zhang, Mengni, Chen, Ni, Sun, Guangxi, Chen, Junru, Ni, Yuchao, Dai, Jindong, Liu, Zhenhua, Tao, Ronggui, Zhang, Xingming, Zhu, Xudong, Zhang, Haoran, Liang, Jiayu, Wang, Zilin, He, Ben, Shen, Pengfei, Zeng, Hao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290811/ https://www.ncbi.nlm.nih.gov/pubmed/34435696 http://dx.doi.org/10.1002/pros.24215

Ejemplares similares

Homologous recombination deficiency (HRD) score in aggressive prostatic adenocarcinoma with or without intraductal carcinoma of the prostate (IDC-P)
por: Zhu, Sha, et al.
Publicado: (2022)

Exosomal TUBB3 mRNA expression of metastatic castration‐resistant prostate cancer patients: Association with patient outcome under abiraterone
por: Zhu, Sha, et al.
Publicado: (2021)

Comparison of Systemic Treatments for Metastatic Castration-Resistant Prostate Cancer After Docetaxel Failure: A Systematic Review and Network Meta-analysis
por: Chen, Junru, et al.
Publicado: (2022)

Plasma Exosomal AKR1C3 mRNA Expression Is a Predictive and Prognostic Biomarker in Patients with Metastatic Castration-Resistant Prostate Cancer
por: Zhu, Sha, et al.
Publicado: (2022)

The efficacy and safety of radical prostatectomy and radiotherapy in high-risk prostate cancer: a systematic review and meta-analysis
por: Wang, Zhipeng, et al.
Publicado: (2020)

The prognostic value of the pretreatment lung immune prognostic index in patients with metastatic hormone-sensitive and castration-resistant prostate cancer
por: Wang, Zhipeng, et al.
Publicado: (2023)

Retraction to the prognostic value of the pretreatment lung immune prognostic index in patients with metastatic hormone-sensitive and castration-resistant prostate cancer
por: Wang, Zhipeng, et al.
Publicado: (2023)

Survival Outcomes of Radical Prostatectomy + Extended Pelvic Lymph Node Dissection and Radiotherapy in Prostate Cancer Patients With a Risk of Lymph Node Invasion Over 5%: A Population-Based Analysis
por: Chen, Junru, et al.
Publicado: (2020)

Mutations in epigenetic regulator KMT2C detected by liquid biopsy are associated with worse survival in prostate cancer patients
por: ZHU, SHA, et al.
Publicado: (2023)

Dynamic multidisciplinary team discussions can improve the prognosis of metastatic castration‐resistant prostate cancer patients
por: Zhu, Sha, et al.
Publicado: (2021)

Efficacy and Safety of Individualized Schedule of Sunitinib by Drug Monitoring in Patients with Metastatic Renal Cell Carcinoma
por: Zhu, Xudong, et al.
Publicado: (2021)

The Adiponectin-AdipoR1 Axis Mediates Tumor Progression and Tyrosine Kinase Inhibitor Resistance in Metastatic Renal Cell Carcinoma
por: Sun, Guangxi, et al.
Publicado: (2019)

The prognostic implication of intraductal carcinoma of the prostate in metastatic castration-resistant prostate cancer and its potential predictive value in those treated with docetaxel or abiraterone as first-line therapy
por: Zhao, Jinge, et al.
Publicado: (2017)

The Impact of Renal Impairment on Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With Tyrosine Kinase Inhibitors
por: Zhang, Haoran, et al.
Publicado: (2020)

The value of transperineal apical prostate biopsy in predicting urethral/apical margin status after radical prostatectomy
por: Dai, Jindong, et al.
Publicado: (2019)

Comparison of Current Systemic Combination Therapies for Metastatic Hormone-Sensitive Prostate Cancer and Selection of Candidates for Optimal Treatment: A Systematic Review and Bayesian Network Meta-Analysis
por: Chen, Junru, et al.
Publicado: (2020)

MicroRNA-106a suppresses prostate cancer proliferation, migration and invasion by targeting tumor-derived IL-8
por: Shen, Pengfei, et al.
Publicado: (2020)

Chronological Liquid Biopsy Reveals the Impact of Platinum-Based Chemotherapy on a Prostate Cancer Patient’s CDK12 Mutation: A Case Report
por: Zhu, Sha, et al.
Publicado: (2022)

The validation of the 2014 International Society of Urological Pathology (ISUP) grading system for patients with high-risk prostate cancer: a single-center retrospective study
por: Liu, Jiandong, et al.
Publicado: (2019)

Integrated multi-omics analyses reveal that BCAM is associated with epigenetic modification and tumor microenvironment subtypes of clear cell renal cell carcinoma
por: Zhao, Junjie, et al.
Publicado: (2022)

The effect of additional chemotherapy on high-risk prostate cancer: a systematic review and meta-analysis
por: Chen, Junru, et al.
Publicado: (2018)

Pelvic lymph node dissection and its extent on survival benefit in prostate cancer patients with a risk of lymph node invasion >5%: a propensity score matching analysis from SEER database
por: Chen, Junru, et al.
Publicado: (2019)

Multidisciplinary Team (MDT) Discussion Improves Overall Survival Outcomes for Metastatic Renal Cell Carcinoma Patients
por: Zeng, Yuhao, et al.
Publicado: (2023)

Differential expressions of PD-1, PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinoma
por: Zhang, Xingming, et al.
Publicado: (2019)

Integrated exome and RNA sequencing of TFE3-translocation renal cell carcinoma
por: Sun, Guangxi, et al.
Publicado: (2021)

The prognosis benefits of adjuvant versus salvage radiotherapy for patients after radical prostatectomy with adverse pathological features: a systematic review and meta-analysis
por: Tao, Ronggui, et al.
Publicado: (2019)

Differential expression of TIM-3 between primary and metastatic sites in renal cell carcinoma
por: Zhang, Xingming, et al.
Publicado: (2019)

Intraductal carcinoma of the prostate
por: Szentirmai, Eszter, et al.
Publicado: (2020)

The association between SPINK1 and clinical outcomes in patients with prostate cancer: a systematic review and meta-analysis
por: Zhang, Xingming, et al.
Publicado: (2017)

Nomogram Models for Distinguishing Intraductal Carcinoma of the Prostate From Prostatic Acinar Adenocarcinoma Based on Multiparametric Magnetic Resonance Imaging
por: Yang, Ling, et al.
Publicado: (2023)

Intraductal carcinoma of the prostate in prostate biopsy samples: correlation with aggressive pathological features after radical prostatectomy and prognostic value in high-risk prostate cancer
por: Zhu, Sha, et al.
Publicado: (2019)

Suppression of α-methylacyl-coenzyme A racemase by miR200c inhibits prostate adenocarcinoma cell proliferation and migration
por: Xie, Hanbing, et al.
Publicado: (2020)

The prevalence and prognosis of next‐generation therapeutic targets in metastatic castration‐resistant prostate cancer
por: Pan, Jian, et al.
Publicado: (2022)

Primary renal mucinous adenocarcinoma masquerading as a giant renal cyst: a case report
por: Zeng, Hong, et al.
Publicado: (2023)

Long noncoding RNA ZEB1-AS1 epigenetically regulates the expressions of ZEB1 and downstream molecules in prostate cancer
por: Su, Wenjing, et al.
Publicado: (2017)

Intraductal Carcinoma of the Prostate: To Grade or Not to Grade
por: Surintrspanont, Jerasit, et al.
Publicado: (2023)

Genomic and transcriptomic features between primary and paired metastatic fumarate hydratase–deficient renal cell carcinoma
por: Liang, Jiayu, et al.
Publicado: (2023)

Radiomic Machine Learning and External Validation Based on 3.0 T mpMRI for Prediction of Intraductal Carcinoma of Prostate With Different Proportion
por: Yang, Ling, et al.
Publicado: (2022)

Downregulation of miR-199a-5p promotes prostate adeno-carcinoma progression through loss of its inhibition of HIF-1α
por: Zhong, Jinjing, et al.
Publicado: (2017)

Predictors of efficacy of corticosteroid switching from abiraterone plus prednisone to dexamethasone in patients with metastatic castration-resistant prostate cancer
por: Ni, Yu-Chao, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8oau9n7qfohcrovfs8rf0qpqh1